You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Mallinckrodt
Dow
Merck
Boehringer Ingelheim

Last Updated: October 2, 2023

CLINICAL TRIALS PROFILE FOR PATADAY TWICE DAILY RELIEF


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Pataday Twice Daily Relief

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00534794 ↗ Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed Merck Sharp & Dohme Corp. Phase 4 2007-10-01 The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis.
NCT01272089 ↗ A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed Alcon Research Phase 4 2011-05-01 The purpose of this study was to evaluate subject perceptions of Olopatadine 0.2%, dosed once-daily, in subjects with allergic conjunctivitis and to record any adverse events as described by the subjects as a part of this post marketing surveillance study.
NCT01450176 ↗ Comparing Patient Satisfaction With Pataday or Bepreve Completed McCabe Vision Center N/A 2011-09-01 The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine hydrochloride 0.2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution 1.5%) two times a day (BID).
NCT01470118 ↗ A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed Allergan Phase 4 2011-10-01 This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.
NCT01732757 ↗ A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed Allergan Phase 4 2012-11-01 This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pataday Twice Daily Relief

Condition Name

Condition Name for Pataday Twice Daily Relief
Intervention Trials
Allergic Conjunctivitis 4
Conjunctivitis, Allergic 2
Eye Allergies 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pataday Twice Daily Relief
Intervention Trials
Conjunctivitis, Allergic 6
Conjunctivitis 6
Drug Hypersensitivity 1
Hypersensitivity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pataday Twice Daily Relief

Trials by Country

Trials by Country for Pataday Twice Daily Relief
Location Trials
United States 6
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pataday Twice Daily Relief
Location Trials
Massachusetts 3
Tennessee 2
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pataday Twice Daily Relief

Clinical Trial Phase

Clinical Trial Phase for Pataday Twice Daily Relief
Clinical Trial Phase Trials
Phase 4 6
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pataday Twice Daily Relief
Clinical Trial Phase Trials
Completed 5
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pataday Twice Daily Relief

Sponsor Name

Sponsor Name for Pataday Twice Daily Relief
Sponsor Trials
Allergan 2
Andover Research Eye Institute 2
Merck Sharp & Dohme Corp. 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pataday Twice Daily Relief
Sponsor Trials
Industry 6
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Medtronic
Colorcon
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.